Risk of Malignant Transformation Arising From Giant Congenital Melanocytic Nevi: A 20-year Single-center Study

Dermatol Surg. 2022 Feb 1;48(2):171-175. doi: 10.1097/DSS.0000000000003341.

Abstract

Background: Although giant congenital melanocytic nevus (GCMN) is regarded as premalignant, the incidence and risk factors of malignant transformation are controversial.

Objective: This study aimed to share the authors' surgical experience with GCMNs and provide data on their demographics, malignant transformation, and prognosis.

Methods: This single-center, consecutive study included 152 patients with GCMN who visited this center from March 2000 to February 2020. Their medical documentation was reviewed retrospectively, and the nevi were classified according to the size as follows: Group 1, 10 to 19.9 cm (n = 45); Group 2, 20 to 39.9 cm (n = 62); and Group 3, ≥40 cm (n = 45).

Results: Seven malignancies were found (4.6%; 4 melanomas, 2 rhabdomyosarcomas [RMS], and 1 malignant peripheral nerve sheath tumor [MPNST]). The risk increased according to the nevus size (2.2% in Group 1, 3.2% in Group 2, and 8.9% in Group 3) but the difference was not statistically significant (p = .3305).

Conclusion: Malignant transformation from GCMN cannot be ignored. It can include transformation into melanoma, RMS, and MPNST. Early surgical resection and regular follow-up should be performed in patients with nevi ≥10 cm.

MeSH terms

  • Cell Transformation, Neoplastic
  • Humans
  • Melanoma* / epidemiology
  • Melanoma* / etiology
  • Melanoma* / surgery
  • Neurofibrosarcoma* / complications
  • Nevus*
  • Nevus, Pigmented* / congenital
  • Nevus, Pigmented* / epidemiology
  • Nevus, Pigmented* / surgery
  • Retrospective Studies
  • Skin Neoplasms* / epidemiology
  • Skin Neoplasms* / pathology
  • Skin Neoplasms* / surgery

Supplementary concepts

  • Melanocytic nevus syndrome, congenital